Jennifer Kim: Okay, that’s helpful. And then my last question, a smaller question, is there anything that drove the higher cost of sales for the quarter?
Nancy Lurker: Yeah, we have a great team, we will see two. And I’m just going to say, and I’ve told our team this. First off we have a great product, YUTIQ is really a terrific product for patients with posterior segment uveitis, the team has done a fantastic job. And they’ve done a fantastic job as well reaching out to retinal specialists over and above just uveitis specialists because they treat posterior segment inflammation as well and uveitis. So they’ve done a fantastic job. I just want to say it’s a tribute to having a high quality team, a sound marketing plan, and how you go about talking about the product that physicians start to realize where the opportunity is. And the product continues to deliver in terms of efficacy and safety.
It just continued to do very well. Now again, I always put caveats because drugs are funny things. Generally, we’ve got a great track record, we continue to have a great track record, never can promise that something couldn’t happen down the road. But right now, it just continues to look great. Scott, I’m going to ask if you want to add anything to that.
Scott Jones: Thank you, Nancy. I would reiterate a lot of the comments that you had. I think, Jennifer, if I heard your question correctly you’re asking about the change in the cost of sales. I think a lot of that is related to just investment, timing of investments that were made for various meetings and some of the ongoing trials that are going on, such as the CALM study, etc. So it was really that was more of a timing issue.
Jennifer Kim: Okay. Alright. Thanks for taking my questions, guys.
Operator: Thank you. One moment for our next question.
George O. Elston: This is George, just to clarify on cost of sales to Jennifer’s question. The big driver, YUTIQ is a bigger mix because of the drop off in DEXYCU. And cost of sales in Q4 in particular, was impacted by a slight provision for remaining DEXYCU inventory because of that drop off. We don’t expect that to continue 2023 forward. And the items that Scott talked about are below the cost of goods line, just to clarify for the callers.
Operator: Thank you. And our next question will come from the line of Yale Jen with Laidlaw. Your line is open.
Yale Jen: Good morning and thanks for taking the questions. So my first question is in terms of the new injector you’re developing. Could you provide a little more color in terms of the specifics so the benefit attributes could provide by this new device?
Nancy Lurker: Oh, sure, Jay go ahead on that, but let me just say that it really is best in class. Well, it’s a — we believe a state, it’s a state of the art for sure. And I would also say could be best in class. It’s just a really, really nice injector. And we’ve obviously tested that with physicians who are using it. So Jay, you can take it from here.
Jay Duker: Yeah, so the current injection system is based on the YUTIQ injector, which was developed well over a decade ago. It’s essentially like a syringe with a plunger and the doctor presses the plunger to get the inserts into the eye. With a state of the art injector you have a trigger or button that you press and the mechanism within the injector delivers in a very controlled manner, the inserts. Now remember, we can inject up to three inserts with a single injection. And we want to do that in a safe and controlled manner. This new injector system allows that. What it also will feature is a visual guide to the doctor that lets him or her know that all the inserts have been delivered. So it’s in a very ergonomic package.
